C. Bissantz

发表

A Real-World Perspective on Molecular Design.

W. Guba, J. Hert, B. Kuhn, 2016, Journal of medicinal chemistry.

Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations.

D. Rognan, C. Bissantz, G. Folkers, 2000, Journal of medicinal chemistry.

High‐Throughput Modeling of Human G‐Protein Coupled Receptors: Amino Acid Sequence Alignment, Three‐Dimensional Model Building, and Receptor Library Screening.

Didier Rognan, Caterina Bissantz, D. Rognan, 2004 .

Conformational Changes of G Protein‐Coupled Receptors During Their Activation by Agonist Binding

Caterina Bissantz, C. Bissantz, 2003, Journal of receptor and signal transduction research.

Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets?

Didier Rognan, Philippe Bernard, Marcel Hibert, 2002, Proteins.

Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators

C. Bissantz, T. Woltering, S. Gatti, 2011, British journal of pharmacology.

Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2

C. Bissantz, T. Woltering, S. Gatti, 2017, Neuropharmacology.

Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2

C. Bissantz, T. Woltering, S. Gatti, 2016, Neuropharmacology.

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

C. Bissantz, D. Nicolau, S. Giovagnoli, 2018, Antimicrobial Agents and Chemotherapy.

1,2,4‐Trisubstituted Cyclopentanes as Platforms for Diversity

C. Bissantz, A. Link, D. Bergstrom, 2012, Archiv der Pharmazie.

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.

A. Bruns, C. Bissantz, E. Pinard, 2020, Journal of medicinal chemistry.

A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.

C. Bissantz, A. Haldimann, E. Nielsen, 2019, The Journal of antimicrobial chemotherapy.

Discovery of RO7185876, a Highly Potent γ-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer's Disease.

C. Bissantz, W. Neidhart, K. Baumann, 2020, ACS medicinal chemistry letters.

Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.

C. Bissantz, J. Moreau, C. Grundschober, 2015, Journal of medicinal chemistry.

Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2019, Antimicrobial Agents and Chemotherapy.

Corrections to A Medicinal Chemist’s Guide to Molecular Interactions

Martin Stahl, Caterina Bissantz, Bernd Kuhn, 2010, Journal of Medicinal Chemistry.

1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2018, Open Forum Infectious Diseases.

Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.

Rainer E. Martin, C. Bissantz, P. Mattei, 2013, Bioorganic & medicinal chemistry letters.

Derives de indol-3-yl-carbonyl-piperidine et piperazine

C. Bissantz, C. Grundschober, H. Ratni, 2006 .

Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX 1 Antagonist SB-674042 and the Selective OX 2 Antagonist N -Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-

C. Bissantz, P. Malherbe, C. Kratzeisen, 2010 .

Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.

C. Bissantz, P. Malherbe, C. Kratzeisen, 2009, Journal of medicinal chemistry.

5-HT 2C Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures

Caterina Bissantz, C. Bissantz, G. Kennett, 2004 .

A Medicinal Chemist’s Guide to Molecular Interactions

B. Kuhn, C. Bissantz, M. Stahl, 2010, Journal of medicinal chemistry.

Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.

F. Diederich, C. Bissantz, C. Lerner, 2012, Acta crystallographica. Section D, Biological crystallography.

Stepwise Design of γ-Secretase Modulators with Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere.

C. Bissantz, W. Neidhart, Lisha Wang, 2020, Journal of medicinal chemistry.

Meropenem-Nacubactam Activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a Neutropenic Murine Lung Infection Model.

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2019, International journal of antimicrobial agents.

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

D. Rognan, C. Bissantz, G. Folkers, 2002, Journal of medicinal chemistry.

Translating pharmacology models effectively to predict therapeutic benefit.

C. Bissantz, B. Krippendorff, S. Dudal, 2022, Drug discovery today.

Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization

W. Spooren, C. Bissantz, P. Malherbe, 2014, Neuropharmacology.

Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.

C. Bissantz, T. Hoffmann, P. Malherbe, 2012, Journal of medicinal chemistry.

Development and application of new methods for the virtual screening of chemical databases

Caterina Bissantz, C. Bissantz, 2002 .

Syntheses and GABA uptake properties of 6-ether- and 6-enol ether-substituted nipecotic acids.

C. Bissantz, G. Schlewer, P. Krogsgaard‐Larsen, 2004, European journal of medicinal chemistry.

High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening

Didier Rognan, Antoine Logean, Caterina Bissantz, 2004, J. Chem. Inf. Model..

Can we discover pharmacological promiscuity early in the drug discovery process?

Wolfgang Guba, Jérôme Hert, Alexander Hillebrecht, 2012, Drug discovery today.

Focused library design in GPCR projects on the example of 5‐HT2c agonists: Comparison of structure‐based virtual screening with ligand‐based search methods

Wolfgang Guba, Martin Stahl, Caterina Bissantz, 2005, Proteins.

Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX1 Antagonist SB-674042 and the Selective OX2 Antagonist N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA)

C. Bissantz, P. Malherbe, C. Kratzeisen, 2010, Molecular Pharmacology.

Me-Talnetant and Osanetant Interact within Overlapping but Not Identical Binding Pockets in the Human Tachykinin Neurokinin 3 Receptor Transmembrane Domains

W. Spooren, C. Bissantz, P. Malherbe, 2008, Molecular Pharmacology.

Safety screening in early drug discovery: An optimized assay panel.

Wolfgang Guba, Christian Kramer, Manfred Kansy, 2019, Journal of pharmacological and toxicological methods.

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models

C. Bissantz, F. Fezza, U. Grether, 2024, Frontiers in pharmacology.